Redhill Biopharma (RDHL) Competitors

Redhill Biopharma has lower revenue, but higher earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

10.0% of Longeveron shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 11.2% of Longeveron shares are owned by insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Redhill Biopharma has a net margin of 0.00% compared to Longeveron's net margin of -1,893.58%. Redhill Biopharma's return on equity of 0.00% beat Longeveron's return on equity.

Longeveron has a beta of -0.31, suggesting that its stock price is 131% less volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 5.05, suggesting that its stock price is 405% more volatile than the S&P 500.

Longeveron currently has a consensus price target of $5.50, indicating a potential upside of 542.45%. Given Longeveron's stronger consensus rating and higher probable upside, equities analysts plainly believe Longeveron is more favorable than Redhill Biopharma.

In the previous week, Longeveron had 4 more articles in the media than Redhill Biopharma. MarketBeat recorded 5 mentions for Longeveron and 1 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.00 beat Longeveron's score of -0.67 indicating that Redhill Biopharma is being referred to more favorably in the news media.

In the previous week, Novogen and Novogen both had 1 articles in the media. Redhill Biopharma's average media sentiment score of 0.00 beat Novogen's score of -1.32 indicating that Redhill Biopharma is being referred to more favorably in the news media.

Novogen currently has a consensus price target of $21.00, indicating a potential upside of 56.13%. Given Novogen's stronger consensus rating and higher probable upside, equities analysts plainly believe Novogen is more favorable than Redhill Biopharma.

Redhill Biopharma has higher revenue and earnings than Novogen.

Novogen has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 5.05, suggesting that its stock price is 405% more volatile than the S&P 500.

30.9% of Novogen shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Redhill Biopharma had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for Redhill Biopharma and 0 mentions for Anebulo Pharmaceuticals. Redhill Biopharma's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Anebulo Pharmaceuticals has a consensus price target of $3.00, indicating a potential upside of 552.17%. Given Anebulo Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Anebulo Pharmaceuticals is more favorable than Redhill Biopharma.

Redhill Biopharma has higher revenue and earnings than Anebulo Pharmaceuticals. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Redhill Biopharma has a beta of 5.05, meaning that its share price is 405% more volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -1.93, meaning that its share price is 293% less volatile than the S&P 500.

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Redhill Biopharma's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 28.1% of Cocrystal Pharma shares are held by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Cocrystal Pharma and Cocrystal Pharma both had 1 articles in the media. Cocrystal Pharma's average media sentiment score of 0.00 equaled Redhill Biopharma'saverage media sentiment score.

Redhill Biopharma has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Cocrystal Pharma presently has a consensus price target of $6.00, suggesting a potential upside of 334.78%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Cocrystal Pharma is more favorable than Redhill Biopharma.

Cocrystal Pharma has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 5.05, suggesting that its stock price is 405% more volatile than the S&P 500.

Redhill Biopharma's return on equity of 0.00% beat Cocrystal Pharma's return on equity.